COMPARISON OF THE EFFECT OF RANIBIZUMAB AND TRIAMCINOLONE ACETONIDE IN DIABETIC MACULAR EDEMA WITH EPIRETINAL MEMBRANE IN PSEUDOPHAKIC PATIENTS | ||||
| Benha Medical Journal | ||||
| Article 4, Volume 39, Special issue (Ophthalmology), January 2022, Page 38-48 PDF (909.02 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/bmfj.2021.80398.1425 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Ahmed ElHussieny Daifalla1; Ahmed AbdelShafy Tabl 1; Marwa AbdelKader ElFouly2; Mohamed Mabrouk Rezk  3
| ||||
| 1Ophthalmology Department, Faculty of Medicine, Benha University, Benha, Egypt | ||||
| 2Ophthalomology department, Research Institute of Ophthalmology, Giza, Egypt | ||||
| 3Ophthalomology department, Research Institute of Ophthalmology, Giza, Egypt. | ||||
| Abstract | ||||
| Background: Macular edema is considered the main cause of visual loss in diabetic retinopathy patients. Aim: The aim of this study is to compare the effectivness of Intravitreal Ranibizumab and Triamcinolone acetonide in management of diabetic macular edema with epiretinal membrane in pseudophakic patients. Methods: In this prospective observational study we compared the efficacy of Intravitreal Ranibizumab and Triamcinolone acetonide on 35 eyes of 28 pseudophakic patients with DME with ERM. BCVA , IOP and CMT were recorded to patients before injection and then at 1st , 4th , 8th and 12th week after injection. Results: BCVA improved from 0.5 (0.3–1.4) to reach 0.2 (0–0.9) LogMAR at 12th week postinjection in the Ranibizumab group and improved from 0.6 (0.5–1.6) to 0.4 (0.1–1.5) LogMAR at 12th week postinjection in TA group. IOP changed from baseline of 19.06±2.9 to 23.17±2.68 at 1st week reaching 19.56±1.72 at 12th week (p < /p> | ||||
| Keywords | ||||
| Ranibizumab; Triamcinolone acetonide; DME; ERM; pseudophakic | ||||
|
Statistics Article View: 168 PDF Download: 366 |
||||
